Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 8/20 | 0.73 |
| ▸ | SRC | P12931 | 7/20 | 0.54 |
| ▸ | JAK2 | O60674 | 3/20 | 0.53 |
| ▸ | JAK3 | P52333 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | YES1 | P07947 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521505 | 0.88 | KDM4E (0.66) | IKBKBSRCJAK2JAK3NEK1 | |
| SCHEMBL3518431 | 0.85 | IKBKB (1.00) | IKBKBSYK | |
| SCHEMBL3521929 | 0.83 | IKBKB (0.67) | IKBKBSRCJAK2JAK3PDGFRB | |
| SCHEMBL3521199 | 0.83 | IKBKB (0.67) | IKBKBSRCJAK2JAK3CHUK | |
| SCHEMBL3520771 | 0.82 | JAK2 (0.58) | IKBKBJAK2JAK3ABL1NEK1 | |
| SCHEMBL3518653 | 0.82 | IKBKB (0.59) | IKBKBJAK2JAK3ABL1NEK1 | |
| SCHEMBL3520398 | 0.82 | JAK2 (0.57) | IKBKBJAK2JAK3ABL1NEK1 | |
| SCHEMBL3519961 | 0.82 | JAK2 (0.57) | IKBKBJAK2JAK3ABL1NEK1 | |
| SCHEMBL3520474 | 0.82 | JAK2 (0.61) | IKBKBJAK2JAK3ABL1NEK1 | |
| SCHEMBL264216 | 0.82 | SRC (0.54) | SRCABL1NEK1PDGFRBYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885SRC 2516/4885JAK2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.